Pre-and Postoperative Circulating Tumour DNA in Patients With Gastrointestinal Stromal Tumour - A Methodological Assessment Study
Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved..
BACKGROUND/AIM: Gastrointestinal stromal tumours (GISTs) harbour genetic aberrations in receptor tyrosine kinase KIT (KIT) or platelet-derived growth factor receptor A (PDGFRA) in 85-90% of the patients. Circulating tumour DNA (ctDNA) is a potential biomarker in patients with GIST. Previous studies investigating ctDNA around surgery in patients with GIST presented divergent results regarding the proportion of patients with detectable ctDNA. This study aimed to 1) investigate the feasibility of detecting and monitoring ctDNA pre-and postoperative, 2) compare two different circulating free DNA (cfDNA) extraction methods, and validate results obtained by next-generation sequencing (NGS) using Real-Time PCR technology.
PATIENTS AND METHODS: Eight patients planned for immediate surgery or surgery after neoadjuvant oncological treatment were included in the study, from whom blood collection was performed pre- and postoperatively for ctDNA analysis. Furthermore, blood samples from six patients with GIST harbouring a point mutation in KIT or PDGFRA in tissues from primary tumours were used for comparison and validation sub-study.
RESULTS: In this explorative study, none of the patients with very low to intermediate risk GIST harboured KIT, or PDGFRA mutated ctDNA in pre-or postoperative blood samples. The methods used for cfDNA extraction gave similar output, and the two methods for ctDNA analysis gave identical results.
CONCLUSION: There is no benefit in analysing ctDNA around surgery in very low to intermediate-risk GIST patients. Larger studies investigating ctDNA in patients with high-risk GIST around surgery are warranted.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
---|---|
Enthalten in: |
Anticancer research - 42(2022), 11 vom: 26. Nov., Seite 5527-5537 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Brinch, Charlotte Margareta [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 28.10.2022 Date Revised 28.10.2022 published: Print Citation Status MEDLINE |
---|
doi: |
10.21873/anticanres.16022 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM348032919 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM348032919 | ||
003 | DE-627 | ||
005 | 20231226035235.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.21873/anticanres.16022 |2 doi | |
028 | 5 | 2 | |a pubmed24n1160.xml |
035 | |a (DE-627)NLM348032919 | ||
035 | |a (NLM)36288871 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Brinch, Charlotte Margareta |e verfasserin |4 aut | |
245 | 1 | 0 | |a Pre-and Postoperative Circulating Tumour DNA in Patients With Gastrointestinal Stromal Tumour - A Methodological Assessment Study |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 28.10.2022 | ||
500 | |a Date Revised 28.10.2022 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. | ||
520 | |a BACKGROUND/AIM: Gastrointestinal stromal tumours (GISTs) harbour genetic aberrations in receptor tyrosine kinase KIT (KIT) or platelet-derived growth factor receptor A (PDGFRA) in 85-90% of the patients. Circulating tumour DNA (ctDNA) is a potential biomarker in patients with GIST. Previous studies investigating ctDNA around surgery in patients with GIST presented divergent results regarding the proportion of patients with detectable ctDNA. This study aimed to 1) investigate the feasibility of detecting and monitoring ctDNA pre-and postoperative, 2) compare two different circulating free DNA (cfDNA) extraction methods, and validate results obtained by next-generation sequencing (NGS) using Real-Time PCR technology | ||
520 | |a PATIENTS AND METHODS: Eight patients planned for immediate surgery or surgery after neoadjuvant oncological treatment were included in the study, from whom blood collection was performed pre- and postoperatively for ctDNA analysis. Furthermore, blood samples from six patients with GIST harbouring a point mutation in KIT or PDGFRA in tissues from primary tumours were used for comparison and validation sub-study | ||
520 | |a RESULTS: In this explorative study, none of the patients with very low to intermediate risk GIST harboured KIT, or PDGFRA mutated ctDNA in pre-or postoperative blood samples. The methods used for cfDNA extraction gave similar output, and the two methods for ctDNA analysis gave identical results | ||
520 | |a CONCLUSION: There is no benefit in analysing ctDNA around surgery in very low to intermediate-risk GIST patients. Larger studies investigating ctDNA in patients with high-risk GIST around surgery are warranted | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Gastrointestinal stromal tumour | |
650 | 4 | |a circulating tumour DNA | |
650 | 4 | |a next-generation sequencing | |
650 | 7 | |a Circulating Tumor DNA |2 NLM | |
650 | 7 | |a Cell-Free Nucleic Acids |2 NLM | |
650 | 7 | |a Receptors, Platelet-Derived Growth Factor |2 NLM | |
650 | 7 | |a EC 2.7.10.1 |2 NLM | |
650 | 7 | |a Protein-Tyrosine Kinases |2 NLM | |
650 | 7 | |a EC 2.7.10.1 |2 NLM | |
650 | 7 | |a Proto-Oncogene Proteins c-kit |2 NLM | |
650 | 7 | |a EC 2.7.10.1 |2 NLM | |
650 | 7 | |a Receptor, Platelet-Derived Growth Factor alpha |2 NLM | |
650 | 7 | |a EC 2.7.10.1 |2 NLM | |
700 | 1 | |a Aggerholm-Pedersen, Ninna |e verfasserin |4 aut | |
700 | 1 | |a Poulsen, Tim Svenstrup |e verfasserin |4 aut | |
700 | 1 | |a Skovrider-Ruminski, Wojciech |e verfasserin |4 aut | |
700 | 1 | |a DE Heer, Pieter |e verfasserin |4 aut | |
700 | 1 | |a Penninga, Luit |e verfasserin |4 aut | |
700 | 1 | |a Krarup-Hansen, Anders |e verfasserin |4 aut | |
700 | 1 | |a Hogdall, Estrid |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Anticancer research |d 1987 |g 42(2022), 11 vom: 26. Nov., Seite 5527-5537 |w (DE-627)NLM012601454 |x 1791-7530 |7 nnns |
773 | 1 | 8 | |g volume:42 |g year:2022 |g number:11 |g day:26 |g month:11 |g pages:5527-5537 |
856 | 4 | 0 | |u http://dx.doi.org/10.21873/anticanres.16022 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 42 |j 2022 |e 11 |b 26 |c 11 |h 5527-5537 |